Nautilus Biotechnolgy, Inc.(NAUT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NAUT Nautilus Biotechnolgy, Inc.

Closed 10-30 16:00:00 EDT

2.73

-0.41

-13.06%

盘后2.75

+0.02+0.73%

19:58 EDT

High3.08	Low2.64	Vol8.07M
Open2.88	D1 Closing3.14	Amplitude14.01%
Mkt Cap346.93M	Tradable Cap181.56M	Total Shares127.08M
T/O22.17M	T/O Rate12.13%	Tradable Shares66.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NAUT","market":"US","secType":"STK","nameCN":"Nautilus Biotechnolgy, Inc.","latestPrice":2.73,"timestamp":1793390400000,"preClose":3.14,"halted":0,"volume":8068888,"hourTrading":{"tag":"盘后","latestPrice":2.7499,"preClose":2.73,"latestTime":"19:58 EDT","volume":91890,"amount":251188.1498,"timestamp":1793404708483,"change":0.0199,"changeRate":0.007289,"amplitude":0.029304},"delay":0,"changeRate":-0.13057324840764334,"floatShares":66505333,"shares":127078855,"eps":-0.461841,"marketStatus":"Closed","change":-0.41,"latestTime":"10-30 16:00:00 EDT","open":2.88,"high":3.08,"low":2.64,"amount":22165138.509344,"amplitude":0.140127,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.461841,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793610000000},"marketStatusCode":5,"adr":0,"listingDate":1596772800000,"exchange":"NASDAQ","adjPreClose":3.14,"preHourTrading":{"tag":"盘前","latestPrice":2.9,"preClose":3.14,"latestTime":"09:29 EDT","volume":105897,"amount":312860.826036,"timestamp":1793366947207,"change":-0.24,"changeRate":-0.076433,"amplitude":0.070064},"postHourTrading":{"tag":"盘后","latestPrice":2.7499,"preClose":2.73,"latestTime":"19:58 EDT","volume":91890,"amount":251188.1498,"timestamp":1793404708483,"change":0.0199,"changeRate":0.007289,"amplitude":0.029304},"volumeRatio":0.547137,"impliedVol":1.6572,"impliedVolPercentile":0.7371},"requestUrl":"/m/hq/s/NAUT/wiki","defaultTab":"wiki","newsList":[{"id":"2678460354","title":"Nautilus Biotechnology price target raised to $4 from $3.50 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2678460354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678460354?lang=en_us&edition=fundamental","pubTime":"2026-10-28 20:21","pubTimestamp":1793190093,"startTime":"0","endTime":"0","summary":"Roth Capital raised the firm’s price target on Nautilus Biotechnology (NAUT) to $4 from $3.50 and keeps a Buy rating on the shares. The company’s Q...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nautilus-biotechnology-price-target-raised-to-4-from-3-50-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nautilus-biotechnology-price-target-raised-to-4-from-3-50-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAUT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678468194","title":"Avantor Raises FY Revenue Growth, Profit Guidance After Q3 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2678468194","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678468194?lang=en_us&edition=fundamental","pubTime":"2026-10-28 18:16","pubTimestamp":1793182583,"startTime":"0","endTime":"0","summary":"Avantor raises FY revenue growth, profit guidance after Q3 beatOverviewUS life science tools firm's Q3 sales rose 4.6%, beating analyst expectationsAdjusted EPS for Q3 beat analyst expectationsCompany","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nL2N46E0EV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0240878834.USD","LU0205193047.USD","LU1815336091.USD","LU0006061336.USD","AVTR","RGEN","LU0106261612.USD","LU0205194284.USD","BK4121","LU0012050646.USD","NAUT","LU0757428866.USD","LU0240877869.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678643761","title":"Government-Funded IP Could Limit Nautilus Biotechnology’s Control, Commercialization and Competitive Edge","url":"https://stock-news.laohu8.com/highlight/detail?id=2678643761","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678643761?lang=en_us&edition=fundamental","pubTime":"2026-10-28 14:01","pubTimestamp":1793167260,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnolgy, Inc. (NAUT) has disclosed a new risk, in the Trade Secrets category. Intellectual property arising from Nautilus Biotechnolo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/government-funded-ip-could-limit-nautilus-biotechnologys-control-commercialization-and-competitive-edge?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/government-funded-ip-could-limit-nautilus-biotechnologys-control-commercialization-and-competitive-edge?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAUT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678108030","title":"Nautilus Biotechnology, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2678108030","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678108030?lang=en_us&edition=fundamental","pubTime":"2026-10-27 21:30","pubTimestamp":1793107853,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology, Inc. reports results for the quarter ended September 30 - Earnings SummaryNautilus Biotechnology, Inc.NAUT.OQreported a quarterly adjusted loss of 12 cents per share for the qu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nL5N46D1KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAUT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678748941","title":"Kiniksa Pharmaceuticals Q3 Arcalyst Revenue Jumps 58%; Raises Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2678748941","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678748941?lang=en_us&edition=fundamental","pubTime":"2026-10-27 19:41","pubTimestamp":1793101308,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals Q3 ARCALYST revenue jumps 58%; raises guidanceOverviewUS biopharma firm's Q3 ARCALYST revenue rose 58% yr/yr to $286 mlnNet income for Q3 more than doubled to $47.3 mln from $1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nL2N46D0GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2089984988.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU0058720904.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU1559883803.SGD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU0566484027.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU1023059063.AUD","LU2242646821.SGD","LU0889565916.HKD","BBH","LU1057294990.SGD","TBXU","IBBQ","BK4585","PBE","LU1236620750.USD","BK4505","LU1983299246.USD","BK4533","BK4534","NAUT","ABOS","PJP","IE0009355771.USD","LU0868494617.USD","LU1571399168.USD","SG9999001440.SGD","BK4539","AMGN","IE00B4R5TH58.HKD","LU2112291526.USD","LU0122379950.USD","LU2242652126.USD","LU2468319806.SGD","BK4581","IBB","IE0002141913.USD","BIB","LU1236620834.HKD","BK4599","BK4566","BK4588","KNSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678920179","title":"Repligen Q3 Revenue Beats Estimates on Higher Demand; Lifts Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2678920179","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678920179?lang=en_us&edition=fundamental","pubTime":"2026-10-27 19:16","pubTimestamp":1793099764,"startTime":"0","endTime":"0","summary":"Repligen Q3 revenue beats estimates on higher demand; lifts outlookOverviewUS bioprocessing tech firm's Q3 revenue rose 11%, beating analyst expectationsQ3 adjusted EPS beat analyst expectationsCompan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nL2N46D0ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU0106261612.USD","LU0757428866.USD","LU0240877869.USD","LU0205194284.USD","LU0012050646.USD","LU1815336091.USD","LU0240878834.USD","NAUT","LU0205193047.USD","RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678120006","title":"Nautilus Biotechnology Q3 Revenue Beats","url":"https://stock-news.laohu8.com/highlight/detail?id=2678120006","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678120006?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:12","pubTimestamp":1793095964,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology Q3 revenue beatsOverviewUS proteomics platform developer's Q3 revenue beat analyst expectationsCompany's Q3 net loss widened from a year earlierOperating expenses increased 10% ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nL2N46D0BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","SG9999002224.SGD","NAUT","PJP","GDOC","LU1935042991.SGD","IBB","IHE","BMED","FHLC","BBH","AMGN","IYH","BK4599","IE00BVYPNV92.GBP","LU0320765646.SGD","LU2471134796.USD","MEDX","PBE","IE000MB6IJN5.SGD","IE00BVYPNW00.USD","BK4559","LU1236620750.USD","FTXH","LU1221951046.USD","JNJ","XLV","LU1989771016.USD","LU2129689514.USD","LU2403377893.USD","LU0345770308.USD","RXL","ABOS","LU1732799900.SGD","IXJ","LU1059921491.USD","IE00BN8TJ469.HKD","IBBQ","LU0234572021.USD","TRUH","TBXU","LU2505996509.AUD","JDOC","LU0058720904.USD","BK4532","IE00BBT3K403.USD","VHT","BK4139","LU0545039389.USD","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678578120","title":"Nautilus Expects up to $6 Million from ARPA-H-Funded SEEDS Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2678578120","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678578120?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:01","pubTimestamp":1793095299,"startTime":"0","endTime":"0","summary":"Nautilus Expects Up to $6 Million From ARPA-H-Funded SEEDS ProjectNautilus Biotechnology expects up to $6 million over four years through the ARPA-H-funded SEEDS research consortium.The consortium, aw","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDL1fSrwS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4585","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210149790.SGD","IE00BQXX3D17.EUR","BCDF","IE00BKPKM429.USD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","BK4588","NAUT","NDAQ","LU0314104364.USD","LU2210150020.SGD","BK4112","BK4121","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678120502","title":"Nautilus Biotechnology Q3 EPS USD -0.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2678120502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678120502?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:01","pubTimestamp":1793095262,"startTime":"0","endTime":"0","summary":"BRIEF-Nautilus Biotechnology Q3 EPS USD -0.12Oct 27 (Reuters) - Nautilus Biotechnology Q3 operating expenses USD 16.947 million.Q3 net income USD -15.636 millionQ3 revenue USD 234 thousand vs. IBES estimate USD 206.2 thousand","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nPLXZ7GN5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAUT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678112084","title":"Nautilus Biotechnology Q3 Operating Expenses USD 16.947 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2678112084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678112084?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:00","pubTimestamp":1793095202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nPLXZ7GN5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAUT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678209631","title":"Press Release: Nautilus Biotechnology Reports Third Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2678209631","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678209631?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:00","pubTimestamp":1793095200,"startTime":"0","endTime":"0","summary":"SEATTLE, Oct. 27, 2026  -- Nautilus Biotechnology, Inc. , a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026.Third Quarter 2026 Business Highlights-- Published a peer-reviewed paper in Nature Methods showing how Iterative. Mapping reveals the proteoforms underlying biology and disease, with. potential to yield new biomarkers and drug targets.-- Shared first development data on oncology proteoform assays, including. AKT1, at World HUPO 2026, showing a performance profile matching Tau and. -- Advanced the proteoform pipeline needed to deliver twenty assays planned. -- Subsequent to quarter end, announced participation in SEEDS, a four-year,multi-center research consortium funded by ARPA-H, with Nautilus. expecting to receive up to $6 million to deploy its Voyager PlatformTM to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","BK4099","NAUT","BK4585","TM","BK4555","BK4121","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677922480","title":"Nautilus Biotechnology, Inc. Expected to Post a Loss of 14 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2677922480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677922480?lang=en_us&edition=fundamental","pubTime":"2026-10-23 20:45","pubTimestamp":1792759509,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology, Inc. <NAUT.OQ> expected to post a loss of14cents a share - Earnings PreviewNautilus Biotechnology, Inc.NAUT.OQNAUT.Ois expected to  show a rise in quarterly revenue when it rep","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nL8N4691BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAUT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675581029","title":"Nautilus Biotechnology Publishes Update to Financial Calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2675581029","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675581029?lang=en_us&edition=fundamental","pubTime":"2026-10-15 20:00","pubTimestamp":1792065658,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology publishes update to financial calendarNautilus Biotechnology will report third-quarter 2026 financial results before market open on Oct. 27, 2026.Management will host a conferen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261015:nNDL6Rvgcl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SG9999014005.SGD","IE00BQXX3D17.EUR","NAUT","LU2210149790.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BCDF","LU2210150020.SGD","BK4121","BK4585","IE00BQXX3C00.GBP","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","NDAQ","SG9999014021.USD","IE00BN0W2V16.EUR","BK4588","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671218332","title":"Nautilus Biotechnology Initiated at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2671218332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671218332?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:40","pubTimestamp":1790674800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAUT/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAUT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571040","title":"Nautilus Biotechnology May Offer up to $300 Million of Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571040","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571040?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:21","pubTimestamp":1789158119,"startTime":"0","endTime":"0","summary":"BRIEF-Nautilus Biotechnology May Offer Up To $300 Million Of Securities - SEC FilingSept 11 (Reuters)-Nautilus Biotechnology, Inc.NAUT.O:NAUTILUS BIOTECHNOLOGY - MAY OFFER UP TO $300 MILLION OF SECURI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAUT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571026","title":"Nautilus Biotechnology files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571026","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571026?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:10","pubTimestamp":1789157423,"startTime":"0","endTime":"0","summary":"16:07 EDT Nautilus Biotechnology (NAUT) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nautilus-biotechnology-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nautilus-biotechnology-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAUT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571258","title":"Nautilus Biotechnology Signs TD Cowen for up to USD 125 Million ATM Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571258","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571258?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:09","pubTimestamp":1789157348,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology signs TD Cowen for up to USD 125 million ATM equity offeringNautilus Biotechnology entered an at-the-market equity distribution agreement with TD Securities (USA) to sell up to ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL6Dw2Dv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAUT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666714475","title":"Nautilus Biotechnology - May Offer up to $125 Mln Common Stock Under Sales Agreement with TD Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2666714475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666714475?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:06","pubTimestamp":1789157176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530GA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAUT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666804845","title":"Leerink Partners Initiates Coverage on Nautilus Biotechnolgy With Outperform Rating, $4 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666804845","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666804845?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954346,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Coverage on Nautilus Biotechnolgy With Outperform Rating, $4 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAUT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666429584","title":"Nautilus Biotechnology initiated with an Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2666429584","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666429584?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:11","pubTimestamp":1788948667,"startTime":"0","endTime":"0","summary":"Leerink initiated coverage of Nautilus Biotechnology (NAUT) with an Outperform rating and $4 price target Published first on TheFly – the ultimate ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nautilus-biotechnology-initiated-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nautilus-biotechnology-initiated-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAUT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nautilus.bio","stockEarnings":[{"period":"1week","weight":0.2077},{"period":"1month","weight":1.3004},{"period":"3month","weight":2.2139},{"period":"6month","weight":0.163},{"period":"1year","weight":1.227},{"period":"ytd","weight":0.6103}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.0068},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.0676},{"period":"1year","weight":0.1192},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.028311},{"month":2,"riseRate":0.666667,"avgChangeRate":0.077747},{"month":3,"riseRate":0.666667,"avgChangeRate":0.104644},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.140189},{"month":5,"riseRate":0.666667,"avgChangeRate":0.004324},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.071677},{"month":7,"riseRate":0.5,"avgChangeRate":-0.093808},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.067162},{"month":9,"riseRate":0.571429,"avgChangeRate":0.075073},{"month":10,"riseRate":0.428571,"avgChangeRate":0.21278},{"month":11,"riseRate":0.5,"avgChangeRate":0.048822},{"month":12,"riseRate":0.5,"avgChangeRate":-0.033204}],"exchange":"NASDAQ","name":"Nautilus Biotechnolgy, Inc.","nameEN":"Nautilus Biotechnolgy, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nautilus Biotechnolgy, Inc.(NAUT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nautilus Biotechnolgy, Inc.(NAUT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nautilus Biotechnolgy, Inc.,NAUT,Nautilus Biotechnolgy, Inc.股票,Nautilus Biotechnolgy, Inc.股票老虎,Nautilus Biotechnolgy, Inc.股票老虎国际,Nautilus Biotechnolgy, Inc.行情,Nautilus Biotechnolgy, Inc.股票行情,Nautilus Biotechnolgy, Inc.股价,Nautilus Biotechnolgy, Inc.股市,Nautilus Biotechnolgy, Inc.股票价格,Nautilus Biotechnolgy, Inc.股票交易,Nautilus Biotechnolgy, Inc.股票购买,Nautilus Biotechnolgy, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nautilus Biotechnolgy, Inc.(NAUT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nautilus Biotechnolgy, Inc.(NAUT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction